Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

CW said it is our sleeper program....A 4 to 6 billion market

Not much of a sleeper program since they have been promoting it at conferences for the last 3 years. [But, I believe, no one took them seriously] NOW it's ready to rock & roll --

Here are some of my posts from March - May of this year & earlier. All longs might want to reread these excerpts carefully as they are indicative of MNTA's plans for their NOVEL drug programs. No wonder the stock is beginning to FLY!

****KEY here - already tested in samples from HUMAN PATIENTS!!


MNTA's Novel drug presentations from 2014 & 2015:

Momenta Pharmaceuticals Announces Presentation of Data Supporting Sialylation Platform
(Ref: GlobeNewswire)
May 2nd, 2014

Excerpts:

Momenta has thoroughly characterized a wide range of IVIg preparations to understand the detailed composition of this plasma-derived product. Using molecular, cellular, and animal models of disease, supplemented by an analysis of samples from human patients treated with IVIg, the company has developed a detailed understanding of the biological basis for the therapeutic effects of IVIg. Momenta scientists now have a broad and comprehensive understanding of the composition of IVIg and its mechanism of action as an anti-inflammatory therapeutic. This research has informed the company's approach to the rational design of several novel, differentiated therapeutic agents.

Dr. Manning will present data that demonstrate the enhanced anti-inflammatory activity of these sialylated agents across a broad range of animal models of autoimmune disease, including inflammatory arthritis, immune thrombocytopenic purpura (ITP), pemphigus, and experimental autoimmune encephalomyelitis (EAE).

http://www.firstwordpharma.com/node/1207611?tsid=17#axzz5A3Y8XHIg

May 5, 2015 PEGS/BOSTON

Selective Modulation of Fc Receptors for Improved Therapy of Orphan Autoimmune Diseases: Lessons from IVIg

Unpublished data: Tony Manning, Ph.D., Vice President, Research, Momenta Pharmaceuticals
Based on extensive characterization of the mechanism of action of IVIg, both in animal models and in humans we rationally designed a series of recombinant drug candidates with the potential to deliver improved therapeutic benefit compared to IVIg. These agents are termed Selective Immunodulators of Fc Receptors (SIF’s), and they selectively modulate the activity of members of the Fcg receptor family. In cell and animal models of immune-complex-mediated autoimmunity, SIF’s display up to 500-fold greater potency than IVIg.

http://www.pegsummit.com/uploadedFiles/PEGS/Agenda/15/PEGS_Final_E.pdf

Monday May 1, 2018
!0:50 A.M.
New Targets and Pathways to Treat Unmet Medical Need in Scleroderma and Fibrotic Diseases

Elma Kurtagic, Ph.D., Principal Scientist, Momenta Pharmaceuticals

Development of novel therapeutics is confounded by our inability to understand the complex basis of disease, resulting in a high failure rate in development and unclear benefit for patients. We developed high-resolution analytics to identify drug targets and patient stratification markers that address unmet medical need in autoimmune disease. This presentation will describe the application of this technology to RA and Scleroderma.

http://www.pegsummit.com/Biologics-for-Autoimmune/